Sentence: Cost-effectiveness of cetuximab , cetuximab plus irinotecan , and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer .
Drug combination annotation:
[{'class': 'POS', 'spans': ['cetuximab', 'irinotecan'], 'is_context_needed': True}]